LWCFA
TVRD

Loring Wolcott & Coolidge Fiduciary Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8
Closed -$5K – 730
2020
Q4 		$5K Buy
+8
New +$4.19K ﹤0.01% 695

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's TVRD Position: Q1 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 8 shares — an estimated $5K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in TVRD in Q4 2020 and held it in 1 quarter. The position peaked at $5K in Q4 2020. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 8 Tvardi Therapeutics shares in Q1 2021, an estimated $5K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Tvardi Therapeutics position peaked at $5K in Q4 2020.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q1 2021, filed 14 Apr 2021.